Is ACTUATE THERAPEUTICS, INC. (ACTU) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 13.0% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.0% / 33% | 13.0% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 0.0% / 33% | 92.7% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 13.0% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 0.0% / 33% | 92.7% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -553.7% | |
| Return on Assets (ROA) | -120.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$22M |
| Free Cash Flow | -$22M |
| Current Ratio | 2.4 |
| Total Assets | $9M |
Price & Trading
| Last Close | $2.27 |
| 50-Day MA | $3.86 |
| 200-Day MA | $6.23 |
| Avg Volume | 72K |
|
52-Week Range
$2.05
| |
About ACTUATE THERAPEUTICS, INC. (ACTU)
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ACTUATE THERAPEUTICS, INC. (ACTU) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ACTUATE THERAPEUTICS, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ACTUATE THERAPEUTICS, INC.'s debt ratio?
ACTUATE THERAPEUTICS, INC.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are ACTUATE THERAPEUTICS, INC.'s key financial metrics?
ACTUATE THERAPEUTICS, INC. has a market capitalization of $51M. Return on equity stands at -553.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.